Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Core Insights - Perspective Therapeutics, Inc. is set to report its third quarter 2025 financial results and provide a business update on November 10, 2025, after market close [1] Company Overview - Perspective Therapeutics, Inc. specializes in radiopharmaceutical development, focusing on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [2] - The company is also developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes through a "theranostic" approach [2] Clinical Programs - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready products for clinical trials and commercial operations [3]